Vice President​/Senior Vice President, Clinical Development

Company Summary

Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability.

Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know‑how, and established regulatory pathways of approved oligonucleotide drugs. Korro’s lead program is Alpha‑1 Antitrypsin Deficiency (AATD). Korro is based in Cambridge, Massachusetts.

We are collaborative and united by a common mission. We are building a company with extraordinary people with an audacious vision to create transformative genetic medicines for prevalent diseases. Our values – Rewrite the future, On the Cutting Edge, Better Together, Dynamically Different, Kindness and Integrity – form the fabric of the organization. They are reinforced daily and serve as key dimensions in the hiring process to help us ensure that Korro is a magnet for outstanding talent and a great place to work.

Join us as we redefine what’s possible in genetic medicine and work to make a lasting impact on human health.

We are seeking an exceptional VP (or SVP) of Clinical Development to lead our clinical strategy and oversee clinical trial execution across a diverse pipeline of RNA editing therapeutics. This role will be instrumental in advancing multiple programs from preclinical development through clinical proof‑of‑concept and beyond, working at the forefront of a transformative new therapeutic modality. Reporting to the Chief Scientific Officer, this position will work in close partnership with the VP of Clinical Operations, VP of Regulatory Affairs and VP Research & Preclinical to ensure seamless execution of Korro’s preclinical and clinical development strategy.

This role will have direct oversight of the Pharmacovigilance function.

• Define and execute clinical development strategy across Korro’s portfolio spanning metabolic diseases, rare diseases, autoimmune conditions, and neurological disorders
• Partner with research, regulatory, and clinical operations to shape program priorities and accelerate paths to proof‑of‑concept
• Lead clinical planning for novel RNA editing programs, establishing precedents for this emerging therapeutic class
• Contribute to business development activities, including evaluation of external opportunities and partnership discussions

• Lead the design and scientific oversight of clinical studies across multiple therapeutic areas and geographies
• Collaborate closely with VP of Clinical Operations to ensure study designs are operationally feasible and efficiently executed
• Establish relationships with key clinical investigators, academic centers, and patient advocacy groups
• Develop clinical protocols, informed consent documents, and study‑related clinical materials
• Oversee medical monitoring activities and ensure rigorous patient safety oversight across all studies
• Drive data interpretation and clinical decision‑making based on emerging trial results

• Provide direct oversight of the Pharmacovigilance function and team
• Ensure robust safety surveillance systems and processes are in place for all clinical and commercial activities
• Lead safety review and assessment of adverse events, including causality assessments and safety signal detection
• Oversee preparation of safety reports (DSURs, PSURs, IND safety reports) and safety sections of regulatory submissions
• Chair Data Safety Monitoring Board interactions and safety review committees
• Develop risk management strategies and safety communication plans
• Ensure compliance…